New drug doubles survival in pancreatic cancer

A groundbreaking medical discovery is offering hope to patients with pancreatic cancer, one of the most aggressive forms of the disease. A new oral medication called daraxonrasib has demonstrated the ability to nearly double survival times in advanced-stage pancreatic cancer cases.

The clinical trial results represent a genuine victory in the fight against a disease that carries the highest mortality rate of all major cancer types. For many elderly patients facing this devastating diagnosis, this discovery may mean precious additional time with their families.

The drug's mechanism of action specifically targets the mutated KRAS gene, which is present in more than 90% of pancreatic tumours. This mutated gene acts as an accelerator for cancer growth, and the new treatment succeeds in blocking and effectively deactivating it.

Pancreatic cancer frequently affects older people, and treatment options have until now been extremely limited. Its pill form makes the new medication more accessible and comfortable for elderly patients compared with traditional intravenous treatments.

For families caring for an older relative diagnosed with pancreatic cancer, this discovery brings a ray of hope during an incredibly difficult time. The additional time gained through this treatment can be crucial for quality of life and for the precious moments spent with loved ones.

Medical experts emphasise that this advance represents only the beginning of a new era in pancreatic cancer treatment. Continued research and the development of similar therapies may bring even greater benefits to elderly patients in the future.